Filter by: patients
Home > Community Treatment Reports and Side Effects > ALS Phase 2 Study NP001 Treatment Report
What is ALS Phase 2 Study NP001?

NCT01281631 is a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS). Other study ID number is NP001-10-002

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
ALS (Amyotrophic Lateral Sclerosis) 32 29 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Participate in clinical trial 6 4 Efficacy_major Efficacy_slight Efficacy_none
Cognitive decline 1 0
Cramps in calf muscles 1 1 Efficacy_cant_tell
no visible efficacy as seen on MRI 1 0

See all 29 patients currently using ALS Phase 2 Study NP001

Mouse over the table for more information

Reported Schedules

Frequently reported dosages based on patients currently using ALS Phase 2 Study NP001. See all 13 dosages ►

  monthly 1 monthly 1 mg monthly 1 other monthly 3 other monthly 5 mg monthly 5 other monthly 3 other weekly 30 min monthly 250 mg monthly
  2 Number of Patients: 2 3 Number of Patients: 3 1 Number of Patients: 1 12 Number of Patients: 12 3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Using ALS Phase 2 Study NP001 (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 4   Course of treatment ended: 80%
Doctor's advice 1   Doctor's advice: 20%
Side effects too severe 1   Side effects too severe: 20%

See all 5 patients who’ve stopped using ALS Phase 2 Study NP001

Reported Duration See details about how long patients take this treatment ▼

Currently Using ALS Phase 2 Study NP001

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Using ALS Phase 2 Study NP001

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of ALS Phase 2 Study NP001

Always
 32 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of ALS Phase 2 Study NP001

Very
 1 3%
Somewhat
 9 28%
A little
 12 38%
Not at all
 10 31%

Cost

Paid out of pocket

Cost of ALS Phase 2 Study NP001

$200+
 8 31%
$100-199
 4 15%
$50-99
 2 8%
$25-49
 2 8%
< $25
 9 35%

Report created on May 24, 2012.